News
Hims & Hers, LifeMD stocks skyrocket after inking deal with Novo Nordisk to sell Wegovy
Pharma giant Novo Nordisk is partnering with telehealth companies to expand access to its blockbuster weight loss drug Wegovy. | Novo Nordisk and Hims & Hers struck a truce after sparring over compounded versions of the pharma giant's branded GLP-1 drugs.
Hims & Hers Health (NYSE:HIMS) stock spikes, risking a short squeeze given its elevated short interest. Read more here.
Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...
Shares of Hims & Hers Health ( HIMS -5.48%) and LifeMD ( LFMD -14.33%) are surging on Tuesday. The companie' stocks had ...
Hims & Hers is an increasingly profitable, vertically integrated telehealth platform with major tailwinds, positioning it as ...
Novo Nordisk appears to be letting compounded GLP-1 bygones be bygones—at least, in one respect. | Novo Nordisk appears to be ...
In essence, Hims & Hers is embracing a "if you can't beat 'em, join 'em" approach that gives their customers more options.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback